Future perspectives on the treatment of hepatocellular carcinoma with cisplatin

Table 2 Hepatic arterial infusion chemotherapy

Author	Country and region	Publication year	Treatment schedule	n	RR (%)	PFS (M)	MST (M)	1yrs (%)	2yrs (%)	3yrs (%)	5yrs (%)
Court et al[18]	USA	2002	CDDP 50 mg/sq (+Radiation) q4w	67	37.0	-	10.7	-	-	-	-
Yoshikawa et al[19]	Japan	2008	CDDP 65 mg/sq q6-8w	80	33.8	-	-	67.5	50.8	-	-
Carr[20]	USA	2000	CDDP 125-200 mg/sq q4-8w	26	42.3	-	19.5	-	-	-	-
Chung et al[21]	Korea	2000	CDDP 2 mg/kg q8w	23	14.0	-	2.5	9	-	-	-
			CDDP 2 mg/kg q8w	19	33.0	-	4.4	27	-	-	-
			IFN-α 3MU. SC. 3/w
Patt et al[22]	USA	1994	CDDP 100 mg/sq, d1	29	41.0	-	15.0	-	-	-	-
			DXR 30-35 mg/sq, d1
			FUDR 60 mg/sq, d1-4
			Leucovorin 15 mg/sq, d1-4
Toyoda et al[23]	Japan	1995	CDDP 5-10 mg/24h, d1-7	21	14.0	-	-	61.1	-	-	-
			5-FU 500 mg/24h, d1-7
Okuda et al[24]	Japan	1999	CDDP 10 mg/1h, d1-5	31	70.9	-	-	-	-	45.7	45.7
			5-FU 250 mg/5h, d1-5 q3-6w
Takayasu et al[25]	Japan	2000	EPI 30 mg/sq, d1, 6	30	42.9	-	-	-	-	-	-
			CDDP 50 mg/sq, d2,7
			ETP 60 mg/sq, d3, 4, 5
Tanaka et al[26]	Japan	2000	CDDP 10 mg/1h, d1-5	77	45.5	-	-	55.8	27.6	18.3	-
			5-FU 250 mg/5h, d1-5 q4w
Ando et al[27]	Japan	2002	CDDP 7 mg/sq 1h, d1-5	48	47.9	-	10.2	-	-	-	-
			5-FU 170 mg/sq 5h, d1-5 x4w
Kaneko et al[28]	Japan	2002	CDDP 75 mg/sq, d1, 15	34	45.0	-	-	24	-	-	-
			5-FU 750 mg/sq, d1, 8, 15, 22
			MTX 30 mg/sq, d1, 8, 15, 22
			leucovorin 30 mg/sq, d1, 8, 15, 22
			IFN-α-2b 3MU. SC, 3/w q4w
Sumie et al[29]	Japan	2003	CDDP 10 mg/1h, d1-5	16	56.3	-	32.4	-	-	-	-
			5-FU 250 mg/5h, d1-5 x4w
Tanioka et al[30]	Japan	2003	CDDP 3 mg/sq 0.5 h, d1-7	38	47.4	-	6.1	-	-	-	-
			5-FU 170 mg/sq continuous d1-7
			x4w q5w
Lin et al[31]	Taiwan	2004	CDDP 10 mg/sq d1-5	53	28.3	-	13.2	-	-	-	-
			MMC 2 mg/sq d1-5
			leucovorin 15 mg/sq d1-5
			5-FU 100 mg/sq continuous d1-5
			x2w q3-4w
Yamasaki et al[32]	Japan	2005	CDDP 10 mg/body d1-5	29	48.3	-	11.8	-	-	-	-
			5-FU 250 mg/body d1-5
			leucovorin 12 mg(or isovorin 12.5 or 6.25 mg) d1-5
Nagai et al[33]	Japan	2007	CDDP 10 mg/h d1-5	37	6.7 vs 31.8	-	7.4 vs 16.3	-	-	-	-
			leucovorin 12 mg/h d1-5	(15 vs 22)
			5-FU 250 mg/sq (4 h vs 22 h)
			x4w
Park et al[34]	Korea	2007	5-FU 500 mg/sq d1-3 q4w	41	22.0	7	12.0	-	-	-	-
			CDDP 60 mg/sq d2

SC: Subcutaneous injection; CDDP: Cisplatin; DXR: Doxorubicin; EPI: Epirubicin; 5-FU: 5-fluorouracil; ETP: Etoposide; MTX: Methotrexate; FUDR: floxuridine; IFN: Interferon; RR: Response rate; PFS: Progression free survival; MST: Median survival time; 1yrs: 1 year survival rate.